NEW YORK, July 10 – Sequenom of San Diego said Tuesday it had sold five MassArray systems, bringing the number sold in the second quarter to nine.
The purchasers include BioServe Biotechnologies, Centagenetix, Indiana University School of Medicine, LGC, and an undisclosed party.
"We continue to experience an increasing demand for our MassArray product line," Toni Schuh, CEO of Sequenom, said in a statement.
"The success of our systems business also affords us the opportunity to expand our efforts to include the systematic identification of disease genes with the most significant impact on human health,” he said.
Sequenom did not say how much the systems sold for, but in the past the company has said that the price of the MassArray is between $400,000 and $1.1 million depending on consumables.
Schuh said that Sequenom hopes to forge licensing deals and partnerships for a sizable number of the 50 candidate disease genes the company has identified, while keeping some of the more interesting targets for internal development.
In May, Sequenom announced that it would acquire Britain’s Gemini Genomics as part of its hstrategy to become a drug developer.